Utility of C-Kit Expression by Immunohistochemistry as a Prognostic and Theranostic Marker in Colorectal Carcinoma

---

Original Article

Author Details : G. Barathi, Leena D. Joseph, S. Rajendiran, Suresh Varadarajan

Volume : 4, Issue : 3, Year : 2017

Article Page : 385-390

Suggest article by email

Get Permission

---

Abstract

Objectives: Targeted therapy is now available for various carcinomas with growth factor receptor mutations. C-Kit, a tyrosine kinase receptor is overexpressed in many epithelial malignancies. The aim of this study is to determine the role of c-Kit (CD117) expression by Immunohistochemistry (IHC) in colorectal carcinoma (CRC) and to correlate the same with tumor grade, stage, nodal status and metastasis.
Methods: This is a retrospective study conducted on paraffin blocks of histopathology proven CRC. Monoclonal antibody detected against c-kit antigen was observed in the cytoplasm and epithelial membrane of the tumour cells and c-Kit expression was given a score based on staining intensity and percentage of cells showing positivity. A statistical analysis using chi square test was performed to find any difference between the various tumor grade, stage, nodal status and metastasis with respect to their c-kit expression by IHC.
Results: c-Kit was negative in 55% of the cases and out of 45% positive cases 3+ positivity was noted in 5% of the cases only. 2+ positivity was seen in 9% and 1+ in 31%. Statistical data showed a p-value of 0.96, 0.70, 0.48 and 0.68 for grade, stage, nodal status and metastasis of the tumor with respect to c-kit expression respectively.
Conclusion: C-kit expression by IHC has only a limited role and is statistically not significant as a prognostic or theranostic marker in CRC. Molecular analysis of the tyrosine kinase receptor mutation is needed to determine its aberrant expression.

Keywords: c-Kit, Colon cancer, Targeted therapy

How to cite : Barathi G, Joseph L D, Rajendiran S, Varadarajan S, Utility of C-Kit Expression by Immunohistochemistry as a Prognostic and Theranostic Marker in Colorectal Carcinoma. Indian J Pathol Oncol 2017;4(3):385-390

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.